COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03742323
Recruitment Status : Recruiting
First Posted : November 15, 2018
Last Update Posted : May 20, 2020
Information provided by (Responsible Party):
PETHEMA Foundation

Brief Summary:
This study will attempt to confirm the hypothesis that Idelalisib may represent a new therapeutic alternative for patients with ALL in a set of particularly complex scenarios: relapsed, refractory to conventional treatments, and old age. For this reason, the primary objective is the overall response rate [ORR, defined as complete response (CR) or CR with partial hematologic recovery (CRh) and response duration (RD) in adult patients with relapsed or refractory ALL, or in adult ALL patients who are not suitable for treatment with conventional therapies.

Condition or disease Intervention/treatment Phase
Acute Lymphoblastic Leukemia Drug: Idelalisib Phase 1 Phase 2

Detailed Description:

Phase I-II multi-site, exploratory, interventional, unmasked, non-randomized, single arm clinical trial. A single drug will be administered in four different, increasing doses to four consecutive cohorts.

The first phase of the study will focus on determining the most effective and tolerated dose of the study drug. The second phase will follow patients to the end to evaluate the safety of the drug.

The dose escalation will be decided by the Study Coordinator, who will evaluate and assess each cohort. Once the cohort of 6 patients is complete, the Coordinator will evaluate patients and, based on the tolerability and efficacy obtained, will decide whether to proceed with the dose escalation, or whether to end the trial The study will remain open until the overall number of participants is achieved; §progressive dose increases (PI) will be discontinued if dose-limiting toxicity (DLT) is observed in more than two patients in the previous cohort, *PI of the dose will only continue (for the third cohort) if at least two patients in the first two cohorts achieve the overall response rate (ORR), that is, complete response (CR) at four weeks from initiation of treatment; ** the study will only move on to the fourth cohort if CR is achieved in at least one of the six patients in the third cohort at four weeks from initiation of treatment; ***microscopy/cytofluorometry; ****complete blood count, microscopy, biochemistry; *****as long as there is no relapse, treatment will continue after the end of the study (planned for 24 months after the start of recruitment); AE, adverse events

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I-II Unmasked, Non-randomized Study Evaluating the Role of Idelalisib in Patients With Acute Lymphoblastic Leukemia (ALL) That is Relapsing or Refractory to Other Treatments, and in Older Patients With ALL for Whom Conventional Treatments Are Not Recommended
Actual Study Start Date : July 1, 2018
Estimated Primary Completion Date : July 7, 2020
Estimated Study Completion Date : January 1, 2022

Arm Intervention/treatment
Experimental: Idelalisib Drug: Idelalisib
Idelalisib Dose: 100, 150, 200 or 300 mg (in four cohorts of six patients each).
Other Name: CAL-101

Primary Outcome Measures :
  1. Overall Response Rate [ Time Frame: 6 months ]
    overall response rate (ORR), defined as CR (blasts in bone marrow aspiration <5%; neutrophils >1x109/L and platelets>100x109/L in peripheral blood) or CR with partial hematologic recovery (RCh) (blasts in bone marrow aspiration <5%; neutrophils<1x109/L and/or platelets <100x109/L in peripheral blood).

  2. Response duration [ Time Frame: 6 months ]
    Time to response duration

Secondary Outcome Measures :
  1. Overall Response Rate in subgroups [ Time Frame: 6 months ]
    Determine ORR in distinct subgroups of ALL (Ph+ and Ph-).

  2. Determine progression free survival (PFS). [ Time Frame: 6 months ]
    Time to progression

  3. Determine overall survival (OS). [ Time Frame: 24 months ]
    Time of overall survival

  4. Percentage of Adverse Events [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥18 years.
  • B-cell precursor ALL, in any of the following cases:

    • Second or subsequent relapses [including after hematopoeitic stem cell transplantation (HSCT)] in patients who are ineligible for subsequent HSCT.
    • Resistance to at least two lines of treatment. Line of treatment is understood as initial treatment y salvage therapy after the first relapse (that may include HSCT).
    • Older adult patients (aged >65 years) for whom standard therapies are not clinically advisable.
  • In patients with Ph+ ALL, failure after receiving at least two treatments with different TKIs (tyrosine kinase inhibitors): imatinib, dasatinib or ponatinib, in patients who are ineligible for subsequent HSCT.
  • ECOG between 0 and 2.
  • Aspartate transaminase (AST) and alanine aminotransferase (ALT) values < two times the upper limit of normal (ULN) and total bilirubin 2 mg/dL.
  • Creatinine <2 mg/dL
  • More than 10% blasts in bone marrow in the two weeks prior to the start of the trial.
  • Women of childbearing potential: must agree to practice abstinence (abstain from having heterosexual sexual relations/contact) or to use one highly effective birth control method (failure rate less than 1%) during the treatment period and for at least 28 day after the last dose of Idelalisib .
  • A woman is considered able to conceive if she is menstruating, is not post-menopausal (≥12 consecutive months without menstruation for no cause other than menopause) and who has not undergone surgical sterilization (removal of ovaries or uterus).
  • Examples of birth control methods with a <1% yearly failure rate include bilateral tubal ligation, vasectomy, proper use of hormonal contraceptives that prevent ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.
  • The feasibility of sexual abstinence should be evaluated with respect to the duration of the trial and the patient's normal lifestyle preferences. Periodic abstinence (for example, the calendar method, ovulation, symptothermal or post-ovulation methods) and the withdrawal method are not acceptable birth control methods.
  • Male patients: must agree to practice abstinence (abstain from heterosexual sexual relations) or use birth control methods, and agree to not donate sperm, as defined below:
  • With female partners of childbearing capacity or pregnant female partner, men must practice total abstinence or use a condom plus one additional birth control method which, combined, have a failure rate of <1% per year during the treatment period, and for at least 4 months after the last dose of Idelalisib to avoid exposure to the fetus. Men must not donate sperm during this same time period.
  • The feasibility of sexual abstinence should be evaluated with respect to the duration of the trial and the patient's lifestyle preferences. Periodic abstinence and the withdrawal method are not acceptable birth control methods.

Exclusion Criteria:

  • Isolated central nervous system relapse.
  • Patients planning to undergo HSCT.
  • Any active systemic fungal, bacterial, or viral infection at the time of inclusion in the study.
  • Grade II-IV active diarrhea.
  • Grade II-IV active liver toxicity.
  • Previous treatment with other PI3K/mTOR inhibitors.
  • Taking any other experimental drug at the time of entering the trial. Patients who have completed a 4-week washout period will be permitted to enrol in the trial.
  • Taking any antineoplastic drugs at the time of entering the trial (an exception is made for patients being treated with hydroxyurea or glucocorticoids. Use of these drugs is allowed up to 24 hours before initiating treatment with Idelalisib ).
  • Patients being treated with moderate or potent CYP3A4 inhibitors or inducers.
  • Patients with Stevens-Johnson Syndrome and toxic epidermal necrolysis.
  • Patients with active chronic hepatitis, including viral hepatitis.
  • Patients with HIV.
  • Medical history of pneumonitis or any baseline lung disorder that, in the investigator's opinion, might worsen the patient's prognosis in the event of opportunistic pneumonia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03742323

Layout table for location information
Complejo Hospitalario A Coruña Not yet recruiting
A Coruña, Spain
Contact: Guillermo Deben, Dr    + 34 981 17 80 00   
Hospital ICO Badalona Recruiting
Badalona, Spain
Contact: José María Ribera, Dr    + 34 934 978 987   
Hospital Clinic de Barcelona Recruiting
Barcelona, Spain
Contact: Jordi Esteve, Dr    +34 93 227 54 00   
Hospital Vall d'Hebrón Recruiting
Barcelona, Spain
Contact: Pere Barba, Dr    + 34 934 89 30 00   
Hospital ICO Hospitalet Recruiting
Hospitalet de Llobregat, Spain
Contact: Santiago Mercadal, Dr    + 34 932 607 733   
Hospital 12 de Octubre Recruiting
Madrid, Spain
Contact: Mª Pilar Martínez, Dr    + 34 91 508 57 31   
H. Morales Meseguer Recruiting
Murcia, Spain
Contact: Mª Luz Amigo, Dr    + 34 968 36 09 00   
H. Virgen de la Victoria Recruiting
Mála, Spain
Contact: Mª José Moreno, Dr    + 34 951 03 20 00   
Hospital Clinico de Salamanca Recruiting
Salamanca, Spain
Contact: Jesús María Hernández-Rivas, Dr    +34 923 291384   
Hospital Marques de Valdecilla Recruiting
Santander, Spain
Contact: Arancha Bermúdez, Dr    + 34 942 20 25 20   
H. Universitario Virgen de Rocío Recruiting
Sevilla, Spain
Contact: José González-Campos, Dr    + 34 955012218   
Hospital Clínico Valencia Recruiting
Valencia, Spain
Contact: Mar Tormo, Dr    961 97 35 00   
Principal Investigator: Mar Tormo         
Hospital Universitario y Politécnico la Fe Recruiting
Valencia, Spain
Contact: Pau Montesinos, Dr    +34 963 86 27 00   
Sponsors and Collaborators
PETHEMA Foundation
Layout table for additonal information
Responsible Party: PETHEMA Foundation Identifier: NCT03742323    
Other Study ID Numbers: REALIB-LLA-2017
First Posted: November 15, 2018    Key Record Dates
Last Update Posted: May 20, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action